Topic:

Chutes and Ladders

Latest Headlines

Latest Headlines

C-suite shuffle: Amgen CFO Peacock resigns

The company named Michael Kelly, an 11-year Amgen veteran, to hold the CFO position on an interim basis.

Teva chooses Erez Vigodman as new CEO

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Former Bristol-Myers R&D chief signs on at VC firm

Sigal is joining New Enterprise Associates, where former MedImmune CEO David Mott has been leading the healthcare crew.

With CEO pick, Teva bets turnaround savvy will trump pharma know-how

Departed CEO Jeremy Levin officially has a successor at Teva Pharmaceutical Industries. As predicted, Erez Vigodman will step into the helmsman's role as of Feb. 11, while interim CEO Eyal Desheh will return to his previous position as CFO, the company said Thursday.

WSJ: Teva close to CEO choice, with acting CEO and ex-Actavis chief still up for the job

Teva Pharmaceutical Industries is said to be close to choosing Israeli executive Erez Vigodman to take its empty CEO chair, but as the Wall Street Journal reports, some other candidates are still in the running.

Just as hep C star Sovaldi makes its debut, Gilead commercial chief says he'll retire

Gilead Sciences just rolled out its much-anticipated hepatitis C treatment Sovaldi (sofosbuvir) last month. Now, the company's commercial chief is saying sayonara. EVP Kevin Young will retire Feb. 4, leaving his team to soldier on alone with the Sovaldi launch.

Rebel Teva shareholder throws his support to presumptive CEO Vigodman

Balky Teva shareholder Benny Landa has fallen in line behind the company's apparent choice for CEO, Erez Vigodman. As the Financial Times reports, Landa is once again circulating an email to fellow major shareholders--but this time to support the company's board rather than attack it.

Mylan has hired away a new India president from Biocon, its partner there

Mylan turned to India's Biocon last year for expertise on making biosimilars. This year, the generic drug maker is turning to Biocon for someone to run its extensive operations in that country.

Genetics startup Agilis names industry vet Zorich CEO

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Cue more drama in Teva's boardroom as its CEO announcement nears

Teva Pharmaceutical Industries appears to be on the verge of naming a replacement for former helmsman Jeremy Levin, but the  Financial Times  reports that shareholders are also pressing for a boardroom change-up that could end with a new occupant for the chairman's seat.